Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia

Bea, A.M. ; Perez-Calahorra, S. ; Marco-Benedi, V. ; Lamiquiz-Moneo, I. ; Jarauta, E. (Universidad de Zaragoza) ; Mateo Gallego, R. (Universidad de Zaragoza) ; Civeira, F. (Universidad de Zaragoza)

Resumen: Background and aims: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown.
Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year.
Results: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction.
Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.

Idioma: Inglés

DOI: 10.1016/j.atherosclerosis.2017.06.009

Año: 2017

Publicado en: Atherosclerosis 263 (2017), 92-96
ISSN: 0021-9150

Factor impacto JCR: 4.467 (2017)

Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 9 / 65 = 0.138 (2017) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 34 / 128 = 0.266 (2017) - Q2 - T1

Factor impacto SCIMAGO: 1.967 - Cardiology and Cardiovascular Medicine (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983

Tipo y forma: Article (PostPrint)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)